[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 293,724
  • Shares Outstanding, K 64,697
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,020 K
  • EBIT $ -59 M
  • EBITDA $ -59 M
  • 60-Month Beta 0.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.39

Options Overview Details

View History
  • Implied Volatility 85.13% (-42.05%)
  • Historical Volatility 99.94%
  • IV Percentile 1%
  • IV Rank 0.39%
  • IV High 691.92% on 03/05/26
  • IV Low 82.73% on 03/23/26
  • Expected Move (DTE 23) 0.73 (15.89%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 459
  • Volume Avg (30-Day) 773
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 11,977
  • Open Int (30-Day) 15,088
  • Expected Range 3.87 to 5.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 2
  • High Estimate $-0.25
  • Low Estimate $-0.26
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) +37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.86 +19.17%
on 06/11/26
5.95 -22.75%
on 05/27/26
-0.79 (-14.66%)
since 05/22/26
3-Month
3.86 +19.17%
on 06/11/26
6.89 -33.24%
on 05/22/26
-0.63 (-12.05%)
since 03/24/26
52-Week
2.87 +60.28%
on 06/25/25
10.08 -54.37%
on 09/22/25
+1.66 (+56.46%)
since 06/24/25

Most Recent Stories

More News
Immuneering Appoints Andrew Gengos as Chief Financial Officer

- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE)...

IMRX : 4.60 (+1.32%)
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related...

IMRX : 4.60 (+1.32%)
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade...

IMRX : 4.60 (+1.32%)
Immuneering's Runway Into Twenty-Twenty-Nine: A Promise That Assumes Everything Goes According to Plan

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 15, 2026 Current Price $5.16 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Runway Into Twenty-Twenty-Nine:...

IMRX : 4.60 (+1.32%)
Immuneering's Runway Into Twenty-Twenty-Nine: A Promise That Assumes Everything Goes According to Plan

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 15, 2026 Current Price $5.16 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Runway Into Twenty-Twenty-Nine:...

IMRX : 4.60 (+1.32%)
Immuneering's Runway Into Twenty-Twenty-Nine: A Promise That Assumes Everything Goes According to Plan

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 15, 2026 Current Price $5.16 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Runway Into Twenty-Twenty-Nine:...

IMRX : 4.60 (+1.32%)
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting -  - Pivotal...

IMRX : 4.60 (+1.32%)
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction?

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 4.60 (+1.32%)
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction?

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 4.60 (+1.32%)

Business Summary

Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 4.80
2nd Resistance Point 4.72
1st Resistance Point 4.66
Last Price 4.60
1st Support Level 4.53
2nd Support Level 4.45
3rd Support Level 4.39

See More

52-Week High 10.08
Fibonacci 61.8% 7.33
Fibonacci 50% 6.47
Fibonacci 38.2% 5.62
Last Price 4.60
52-Week Low 2.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.